All In Biotech

Drug Trial Radar · NCT06513312

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Persistence, Safety, Acceptability, and Pharmacokinetics of Twice Yearly Long-acting Subcutaneous Lenacapavir for HIV Pre-Exposure Prophylaxis (PrEP) in People Who Would Benefit From PrEP

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

268

Actual

Start

Oct 7, 2024

Primary completion

May 28, 2026

Study completion Nov 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goals of this clinical study are to learn more about the study drug lenacapavir (LEN), by comparing the consistent and continuous use of LEN and emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada®) (F/TDF), then by observing the safety of LEN and F/TDF, evaluating the acceptability of LEN injections and oral F/TDF, and observe how LEN moves throughout the body in people who would benefit from pre-exposure prophylaxis (PrEP). The primary objective of this study is to compare LEN and F/TDF consistent and continuous use among people who would benefit from PrEP.

Conditions

  • Pre-Exposure Prophylaxis of HIV Infection

Interventions

  • Lenacapavir InjectionDrug

    Administered subcutaneously

  • Lenacapavir TabletDrug

    Administered orally

  • Emtricitabine/tenofovir disoproxil fumarate (F/TDF)Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with LEN and F/TDF Persistence through 52 WeeksTime frame: Up to Week 52

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Hopital Avicenne

    Bobigny, France

  • Hopital Europeen Marseille

    Marseille, France

  • CHU Nice Archet

    Nice, France

  • Hopital Saint Louis - Assistance Publique des Hopitaux de Paris

    Paris, France

  • APHP Hopital Saint-Antoine

    Paris, France

  • APHP Bichat Claude-Bernard Hospital

    Paris, France

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham Heartlands Hospital

    Birmingham, United Kingdom

  • Clinical Research Facility, University Hospitals Sussex NHS Foundation Trust

    Brighton, United Kingdom

  • Axess Sexual Health, Liverpool University Hospitals NHS Trust

    Liverpool, United Kingdom

  • Grahame Hayton Unit, Ambrose King Centre, Royal London Hospital, Barts Health NHS Trust

    London, United Kingdom

  • Homerton Healthcare NHS Foundation Trust, Homerton University Hospital

    London, United Kingdom

  • Caldecot Centre, Kings College Hospital, Kings College Hospital NHS Foundation Trust

    London, United Kingdom

  • Chelsea and Westminster Hospital NHS Foundation Trust, Clinical Research Facility, Chelsea and Westminster Hospital

    London, United Kingdom

  • Manchester University NS Foundation Trust

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.